Introduction {#sec1}
============

Type II alveolar epithelial cells (AECs) are a major cellular component of the distal lung epithelium, where they secrete pulmonary surfactant and generate type I AECs that cover most of the surface area of the alveoli ([@bib28; @bib23]). The stepwise differentiation of human pluripotent stem cells (hPSCs), including human embryonic stem cells (hESCs) and induced pluripotent stem cells (hiPSCs), into lung epithelial cells would help to elucidate the etiologies of human lung diseases and create novel treatments, and has been reported in both proximal airway cells ([@bib17; @bib29; @bib4]) and distal lung epithelial cells ([@bib7; @bib5; @bib9]). Currently, however, there are no surface markers that can be used to purify human NKX2-1^+^ "ventralized" anterior foregut endoderm cells (VAFECs) as alveolar epithelial progenitor cells (AEPCs), although NKX2-1 is an early marker of lung and thyroid development ([@bib13]). Here, we report the efficacy of carboxypeptidase M (CPM) as a surface marker of AEPCs for generating type II AECs.

Results {#sec2}
=======

Identification of CPM as a Marker of NKX2-1^+^ VAFECs {#sec2.1}
-----------------------------------------------------

We hypothesized that identifying a surface marker for NKX2-1^+^ VAFECs would be helpful for isolating a homogeneous population of AEPCs without establishing *NKX2-1* reporter cell lines. We constructed a stepwise protocol to induce hPSCs to AECs ([Figure 1](#fig1){ref-type="fig"}A). On day 0, previously established hPSCs were seeded ([@bib27; @bib25; @bib19; @bib20]) following single-cell enzymatic dissociation ([@bib10]), resulting in definitive endodermal cells (DECs) at an efficiency of ≥80% ([Figure S1](#app3){ref-type="sec"}A available online). In step 2, the DECs were differentiated to anterior foregut endodermal cells (AFECs) ([@bib7]) at an efficiency of ≥88% ([Figure S1](#app3){ref-type="sec"}B). In step 3, the concentrations of all-*trans* retinoic acid, CHIR99021, and BMP4 were optimized for seven hPSC lines for differentiation into NKX2-1^+^FOXA2^+^ cells, attaining an efficiency of 57.0%--77.5% ([Figures 1](#fig1){ref-type="fig"}C and 1D; [Supplemental Experimental Procedures](#app3){ref-type="sec"}). In step 4, cells were cultured in medium containing FGF10 for 7 days. In step 5, the cells were differentiated in medium containing dexamethasone, 8-Br-cAMP, 3-isobutyl-1-methylxanthine, and KGF ([@bib6; @bib14]). We confirmed induction of AECs by detecting *SFTPB* and *SFTPC* using RT-PCR and double staining SFTPC and SFTPB with NKX2-1 ([Figures S1](#app3){ref-type="sec"}C and S1D). Transcription factors were analyzed by quantitative RT-PCR (qRT-PCR; [Figure 1](#fig1){ref-type="fig"}B). *SOX17*, *FOXA2*, *GATA6*, and *SOX2* were compatibly changed on day 6 and day 10 as previously described ([@bib7]). On day 14, *NKX2-1*, *GATA6*, *ID2*, *SOX9*, and *HOPX* levels simultaneously increased. Interestingly, *NKX2-1*, *GATA6*, and *HOPX* levels decreased on day 21 and then increased again on day 25. The levels of other organ lineage markers were found to be limited from day 0 to day 25 ([Figure S1](#app3){ref-type="sec"}E).

In order to identify candidate markers of VAFECs, we performed a microarray analysis to compare the global gene-expression patterns of AFECs (day 10) and VAFECs (day 14) in 201B7 hiPSCs. *CPM* and *NKX2-1* were remarkably upregulated on day 14 ([Figures 1](#fig1){ref-type="fig"}E and [S1](#app3){ref-type="sec"}F). In immunofluorescence (IF) staining, CPM and NKX2-1 increased from day 10 to day 14 ([Figure 1](#fig1){ref-type="fig"}F), whereas EPCAM and FOXA2 did not appear to change ([Figure S1](#app3){ref-type="sec"}G). Although CPM was reported to be a marker of type I AECs ([@bib18]), only *CPM* drastically increased on day 14 in a similar pattern to *NKX2-1*, in contrast to other markers of type I AECs (*AQP5* and *CAV1*) ([Figure S1](#app3){ref-type="sec"}H). On day 25, the various airway markers, including distal lung transcription factors (SOX9 and NKX2-1), type II AEC markers (SFTPB and SFTPC), and a club cell marker (SCGB3A2), were expressed in the CPM^+^ cells. KRT5, a marker of basal cells, was not expressed in the CPM^+^ cells ([Figure 1](#fig1){ref-type="fig"}G).

In fetal human lung at 18.5 weeks of gestation, SFTPC and T1α were expressed separately ([Figure S1](#app3){ref-type="sec"}I), while CPM was expressed in NKX2-1^+^, SFTPC^+^, and T1α^+^ cells ([Figure 1](#fig1){ref-type="fig"}H), thus indicating that CPM is expressed in both type I and II AECs in the fetus. The sequential expression of CPM was confirmed in NKX2-1^+^ cells of fetal murine lungs at embryonic day 12.5 (E12.5), E15.5, and E17.5 ([Figure 1](#fig1){ref-type="fig"}I). For thyroid lineage cells, which differentiated from NKX2-1^+^ VAFECs, CPM was found to be negative in both NKX2-1^+^ cells and PAX8^+^ epithelial cells, but weakly positive in PECAM^+^ endothelial cells in the adult human samples ([Figure S1](#app3){ref-type="sec"}J). In E17.5 fetal and adult murine thyroids, CPM was also negative in NKX2-1^+^ and PAX8^+^ cells ([Figure S1](#app3){ref-type="sec"}K), suggesting that CPM is a lung-lineage marker of VAFECs.

Isolation of NKX2-1^+^ VAFECs Using Anti-CPM^+^ Antibody {#sec2.2}
--------------------------------------------------------

As CPM is a membrane-bound surface protein, we performed flow cytometry with anti-EPCAM and anti-CPM antibodies after dissociating VAFECs on day 14 ([Figures 2](#fig2){ref-type="fig"}A and [S2](#app3){ref-type="sec"}A). We then sorted EPCAM^+^CPM^+^ and EPCAM^+^CPM^−^ cells and examined the global gene-expression patterns of these two populations using microarrays. We screened 560 probes with a false discovery rate (FDR)-adjusted p value of \<0.05 among 54,675 probes. Gene clustering was performed in 336 probes that differed between the EPCAM^+^CPM^+^ and EPCAM^+^CPM^−^ cells with a fold change (FC) cutoff value of 2.0 ([Figures 2](#fig2){ref-type="fig"}B and [S2](#app3){ref-type="sec"}B). Of the clustered genes with the highest expression in the EPCAM^+^CPM^+^ cells, *CPM* ranked among the top five probes with a log FC of \>6, as expected. Importantly, the log FCs of two probes for *NKX2-1* were 4.89 and 4.82, respectively. *FOXA1*, *FOXA2*, *HOPX*, and *GATA6* were also included in the list of upregulated genes with log FCs of 3.79, 3.06, 3.61, and 3.29, respectively. Next we sorted the CPM^+^ cells using a magnet-activated cell sorting (MACS) system to increase the yield, as almost all of the CPM^+^ cells were EPCAM^+^ cells (96.7% ± 2.1% of CPM^+^ cells; [Figure 2](#fig2){ref-type="fig"}A). After MACS-based sorting, the proportion of CPM^+^ cells in three populations (presorting, positive selection, and negative selection) was 63.4% ± 5.8%, 98.8% ± 0.4%, and 34.0% ± 7.8%, respectively, by flow cytometry ([Figure 2](#fig2){ref-type="fig"}C). We then evaluated the proportion of positive NKX2-1^+^ cells among the MACS-sorted CPM^+^ and CPM^−^ cells using IF staining (93.0% ± 1.0% versus 29.0% ± 1.0%; [Figure S2](#app3){ref-type="sec"}C) and flow cytometry (92.3% ± 0.7% versus 22.2% ± 2.3%; [Figure S2](#app3){ref-type="sec"}D). Because a portion of the CPM^+^ cells appeared to be sorted according to MACS-based CPM negative selection, we investigated the average proportion of NKX2-1^+^ cells among the fluorescence-activated cell sorting (FACS)-sorted CPM^+^ and CPM^−^ cells using IF staining (89.9% ± 0.4% versus 4.5% ± 1.7%; [Figure 2](#fig2){ref-type="fig"}D). Following CPM-based purification on day 14, *CPM* increased significantly from 0.74-fold ± 0.12-fold to 4.94-fold ± 0.51-fold of that observed in the fetal human lung (n = 5), while *NKX2-1* increased from 0.41-fold ± 0.10-fold to 1.95-fold ± 0.36-fold (n = 5) on qRT-PCR ([Figure 2](#fig2){ref-type="fig"}E). We then applied this method to purify AECs on day 25. *CPM, NKX2-1*, *SFTPA2*, *SFTPB*, *SFTPC*, *DCLAMP*, *SCGB1A1*, and *SCGB3A2* were significantly increased in the CPM^+^ cells (n = 5); however, the level of *SFTPC* was extremely low compared with that observed in the fetal lung. *NGFR*, a marker of proximal airway basal stem cells ([@bib24]), was significantly decreased in the CPM^+^ cells (n = 5; [Figure 2](#fig2){ref-type="fig"}F).

Generation of *SFTPC-GFP* Knockin Reporter hPSCs {#sec2.3}
------------------------------------------------

In order to investigate whether CPM is a potential surface marker of AEPCs, we generated *SFTPC-GFP* knockin reporter hPSC lines from 201B7 hiPSCs using BAC-based homologous recombination methods ([@bib15]; [Figure 3](#fig3){ref-type="fig"}A; [Supplemental Experimental Procedures](#app3){ref-type="sec"}), as SFTPC is the most specific marker of type II AECs. Following electroporation of the targeting vectors, 12 of 55 G418-resistant clones were found to have a heterozygous deletion of the genomic endogenous *SFTPC*-coding region ([Figure 3](#fig3){ref-type="fig"}B). The *pgk-Neo* cassette was removed via electroporation of the Cre-expression vector ([Figure 3](#fig3){ref-type="fig"}C), and normal karyotypes of the A17-14 and B2-3 clones were confirmed ([Figure S3](#app3){ref-type="sec"}). The genomic copy number was calculated as previously described ([@bib15]). The parental 201B7 (data not shown), A17-14, and B2-3 clones have two copies of the *SFTPC* gene loci, in contrast to the A17-13 clone, in which random transgenic integration is supposed to have occurred, as indicated by three copies of the loci ([Figure 3](#fig3){ref-type="fig"}D). No copy-number variation was detected for the B2-3 clone, whereas a copy-number loss at chromosome 16 q23.3 and gain at chromosome 20 p13 were detected for the A17-14 clone (data not shown). Both *SFTPC-GFP* reporter hPSCs were then differentiated to the end of step 5 and GFP^+^ and GFP^−^ cells were obtained by FACS after the CPM^+^ cells were sorted using MACS ([Figure 3](#fig3){ref-type="fig"}E). We confirmed the correlation between *GFP* and *SFTPC* on RT-PCR ([Figure 3](#fig3){ref-type="fig"}F). GFP was detected in SFTPC^+^, SFTPB^+^, and NKX2-1^+^ cells for both clones ([Figure 3](#fig3){ref-type="fig"}G).

Alveolar Differentiation from CPM^+^ VAFECs in 3D Coculture {#sec2.4}
-----------------------------------------------------------

We attempted 2D differentiation, reseeding the CPM^+^ *SFTPC-GFP* reporter hPSCs purified from VAFECs on day 14 onto Matrigel-coated, 96-well plates. After 14 days of differentiation in step 5 medium, SFTPB became positive in the reseeded CPM^+^ cells ([Figure S2](#app3){ref-type="sec"}E); however, *SFTPC* was almost negative ([Figure S4](#app3){ref-type="sec"}D, condition b). We obtained similar results when we sorted and reseeded CPM^+^ cells on day 23 ([Figure S2](#app3){ref-type="sec"}F). The discrepancy between the expression of SFTPB and SFTPC in developing human lungs was previously reported ([@bib11]). Therefore, we hypothesized that some missing factors are important for the coexpression of SFTPB and SFTPC. We then adopted a 3D coculture with fetal human lung fibroblasts (FHLFs) obtained at 17.5 weeks of gestation ([Figure 4](#fig4){ref-type="fig"}A). CPM^+^ cells purified from VAFECs on day 14 and FHLFs were mixed at a ratio of 1:50 and reseeded onto cell inserts. After 10 days of differentiation in step 5 medium, GFP became positive in some spheroids ([Figure 4](#fig4){ref-type="fig"}B). The spheroids were subsequently examined with a transmission electron microscope and lamellar-body-like structures were noted ([Figure 4](#fig4){ref-type="fig"}C). On hematoxylin-and-eosin staining, cyst-like spheroids consisting of pseudostratified, columnar, or cuboidal cells with dark pink cytoplasm were observed in the CPM^+^ cell-derived spheroids, whereas small pieces of spheroids consisting of cuboidal cells with clear cytoplasm were noted in the CPM^−^ cell-derived spheroids ([Figure S4](#app3){ref-type="sec"}A). On IF staining, CPM and NKX2-1 were double positive in most CPM^+^ cell-derived spheroids, while GFP and SFTPC were double positive in some spheroids ([Figure 4](#fig4){ref-type="fig"}D). In the CPM^−^ cell-derived spheroids, EPCAM was positive, whereas no CPM^+^ or NKX2-1^+^ cells were identified ([Figure S4](#app3){ref-type="sec"}B). SFTPA, SFTPB, SFTPC, and SFTPD (representative markers of type II AECs) were positive in the CPM^+^ cell-derived spheroids ([Figure S4](#app3){ref-type="sec"}C). AQP5^+^ cells were adjacent to SFTPC^+^ cells in some spheroids ([Figure 4](#fig4){ref-type="fig"}D). ID2 and SOX9 (markers of differentiation into the distal lung-lineage fate) were positive in some NKX2-1^+^ and CPM^+^ cells, respectively ([Figure S4](#app3){ref-type="sec"}C). Next, we trypsinized the cells in 3D structures and determined the proportion of SFTPC-GFP^+^ cells, detecting 3.82% ± 0.50% cells obtained from the CPM^+^ cell-derived 3D structures and 0.29% ± 0.03% cells obtained from the CPM^−^ cell-derived structures including fibroblasts ([Figure 4](#fig4){ref-type="fig"}E). Excluding the fibroblasts, the ratio of the number of SFTPC-GFP^+^ cells to that of EPCAM^+^ cells was calculated to be 9.81% ± 1.81% in the CPM^+^ cell-derived spheroids and 1.07% ± 0.16% in the CPM^−^ cell-derived spheroids. Almost all of the GFP^+^ cells sorted by FACS were SFTPC^+^, whereas the GFP^−^ cells were SFTPC^−^ ([Figure 4](#fig4){ref-type="fig"}F). The levels of alveolar markers (*SFTPB* and *SFTPC*), rather than club cell markers (*SCGB1A1* and *SCGB3A2*), were significantly elevated following the 3D coculture differentiation of CPM^+^ cells derived from three hPSC lines (H9 hESCs and parental 201B7 and 604A1 hiPSCs) compared with the 2D differentiation employing the three protocols separately starting on day 14 ([Figure 1](#fig1){ref-type="fig"}A; [@bib7; @bib14]) and the 3D coculture differentiation of CPM^−^ cells ([Figure 4](#fig4){ref-type="fig"}G). Interestingly, the levels of *SFTPB* and *SFTPC* were quite low for 585A1 hiPSCs, suggesting that the concentration of retinoic acid required to induce NKX2-1^+^ VAFECs in step 3 is less important for subsequent differentiation into AECs than the difference in the cell lines or donors. Moreover, the expression of *SFTPB* and *SFTPC* was small for the 2D and 3D differentiation of CPM^+^ cells alone or FHLFs alone ([Figure S4](#app3){ref-type="sec"}D). Finally, other cell-type markers (*AQP5* \[type I AECs\], *FOXJ1* \[ciliated cells\], and *AGR2* \[goblet cells\]) appeared to be elevated in the CPM^+^ cell-derived structures rather than in the CPM^−^ cell-derived structures, suggesting that cell-type markers other than club-cell markers were expressed in the CPM^+^ cell-derived spheroids. *KRT5* (a basal cell marker, possibly including both airway and esophageal basal cells) was exclusively expressed in the CPM^−^ cell-derived structures. In addition, *PAX8* (a thyroid marker), *PAX6* (a neuron marker), and the other foregut endodermal lineage cells (*FOXN1*, *ALB*, and *PDX1*) were only minimally or slightly induced following 3D coculture differentiation ([Figure S4](#app3){ref-type="sec"}E).

Discussion {#sec3}
==========

In this work, we identified CPM as a surface marker that is expressed in NKX2-1^+^ VAFECs, including AEPCs, and demonstrated that the CPM^+^ cell-derived spheroids obtained via 3D coculture differentiation with FHLFs enabled more efficient differentiation to AECs than did 2D differentiation. The gene-expression pattern of *CPM* in developing lungs has not received significant attention, although in situ hybridization of *Cpm* in anterior DECs as early as E7.5 in mice has been reported ([@bib26]). Our data from IF staining of murine fetal lungs ([Figure S1](#app3){ref-type="sec"}I) also suggest that lineage-tracing studies may provide answers to the following questions: Is Cpm a possible "specific" marker of lung-lineage progenitor cells such as Shh ([@bib8]), Id2 ([@bib21]), and Nkx2-1 ([@bib14])? What is the relationship between CPM^+^ cells and bipotent cells that are capable of generating type I and type II AECs ([@bib2])? Do CPM^+^ cells differentiate into type II AECs directly or indirectly via SFTPC^+^SCGB1A1^+^ cells ([@bib12; @bib22])? Furthermore, the present study suggests that a 3D microenvironment and coculture with FHLFs are important factors in the differentiation of progenitor cells into AECs rather than club cells. Although maintaining type II AECs in 2D conditions is often difficult ([@bib3; @bib30]), 3D conditions have recently been applied with better outcomes ([@bib30; @bib16; @bib1]). Therefore, our 3D differentiation protocol appears to be a reasonable approach for maintaining differentiated type II AECs, although methods for expanding such cells for longer periods should be established in the next step.

The limitations of the present study include the fact that we were unable to demonstrate whether CPM is a more appropriate marker for lung-lineage cells than NKX2-1. Future studies focusing on the possible contribution of NKX2-1^−^CPM^+^ cells and/or NKX2-1^+^CPM^−^ cells to the differentiation of lung epithelial cells may resolve this issue, although we found only two isolatable populations of NKX2-1^+^CPM^+^ and NKX2-1^−^CPM^−^ cells using the present protocol. In addition, we were unable to demonstrate the highest induction efficiency of AECs, as recently described ([@bib5]), although we employed a different method for evaluating efficiency using *SFTPC-GFP* reporter hPSCs. Another limitation is that the functions of the induced AECs remain to be elucidated.

Nevertheless, the methods applied in the present study to induce and isolate AEPCs using CPM and consequently generate alveolar epithelial spheroids in a stepwise fashion may help to elucidate the complicated differentiation of human AECs and open the door for the development of new strategies for in vitro toxicology and cell replacement therapy, as well as screening for therapeutic drug compounds, in the future.

Experimental Procedures {#sec4}
=======================

2D Differentiation {#sec4.1}
------------------

CHIR99021 (Axon Medchem), an activator of canonical Wnt signaling, was substituted for WNT3A ([@bib15]). For details regarding the protocols used for each differentiation medium, see the [Supplemental Experimental Procedures](#app3){ref-type="sec"}.

3D Differentiation {#sec4.2}
------------------

The protocol for the 3D culture was modified from a previous report ([@bib1]). For further details, see the [Supplemental Experimental Procedures](#app3){ref-type="sec"}.

Ethics {#sec4.3}
------

The use of H9 hESCs was approved by the Ministry of Education, Culture, Sports, Science and Technology (MEXT) of Japan. Human ethics approval was obtained from the Institutional Review Board and Ethics Committee of Kyoto University Graduate School and Faculty of Medicine. Animal ethics approval was obtained from the Animal Ethics and Research Committee of Kyoto University.

Statistical Analysis {#sec4.4}
--------------------

Values are expressed as the mean ± SEM and "n" stands for the number of independent experiments. Two-tailed Student's t test was performed to identify significant differences between two conditions of qRT-PCR.
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![Identification of CPM as a Candidate Marker of NKX2-1^+^ VAFECs\
(A) Stepwise differentiation to AECs from hPSCs.\
(B) Gene-expression levels of transcription factors from day 0 to day 25 (n = 3). Each value was normalized to the level of *β-ACTIN*. The relative expression level was scored with the maximum value set to 1.0.\
(C) Induction efficiency of VAFECs analyzed by scoring the number of FOXA2^+^ and NKX2-1^+^ cells relative to the total number of nuclei in an average of ten randomly selected images (n = 3).\
(D) FOXA2^+^NKX2-1^+^ VAFECs derived from 201B7 hiPSCs.\
(E) Scatterplots comparing the global gene-expression profiles of AFECs (day 10) and VAFECs (day 14). *CPM* (arrows) and *NKX2-1* (arrowheads) are noted. The lines beside the diagonal line indicate a 2-fold cutoff change between the AFECs and VAFECs.\
(F) Simultaneous increases of CPM and NKX2-1 detected by IF staining of AFECs (day 10) and VAFECs (day 14).\
(G) CPM detected in NKX2-1^+^, SOX9^+^, SFTPB^+^, SFTPC^+^, and SCGB3A2^+^ cells, but not in KRT5^+^ cells, on day 25.\
(H) CPM detected in NKX2-1^+^ lung epithelial cells in fetal human lung.\
(I) CPM in E12.5, E15.5, and E17.5 murine lungs.\
Error bars show SEM. Scale bars, 100 μm. See also [Figure S1](#app3){ref-type="sec"} and [Tables S1](#app3){ref-type="sec"} and [S2](#app3){ref-type="sec"}.](gr1){#fig1}

![Isolation of CPM^+^ VAFECs Using Anti-CPM Antibody\
(A) Flow cytometry of VAFECs. EPCAM^+^CPM^+^ (Q2) and EPCAM^+^CPM^−^ cells (Q4) were isolated on day 14 (n = 3).\
(B) Hierarchical clustering heatmaps of 336 genes with differences of \>2-fold (FDR-adjusted p \< 0.05) comparing EPCAM^+^CPM^+^ cells with EPCAM^+^CPM^−^ cells. The cluster of genes increased as the greatest fold change was magnified.\
(C) Flow cytometry of MACS-sorted CPM^+^ and CPM^−^ cells from VAFECs (n = 3).\
(D) NKX2-1^+^ cells in FACS-sorted CPM^+^ and CPM^−^ cells derived from VAFECs analyzed by scoring the number of NKX2-1^+^ cells relative to the total number of nuclei in an average of five randomly selected images (n = 3).\
(E) Levels of *CPM* and *NKX2-1* on day 14 before and after MACS-based purification of CPM^+^ cells on qRT-PCR (n = 5).\
(F) Levels of AEC and club-cell markers and *NGFR*, a proximal airway stem cell marker, on day 25 before and after MACS-based purification of CPM^+^ cells (n = 5).\
The gene-expression level observed in the fetal lungs was set at one. Values are presented as the mean ± SEM. Error bars show SEM. \#p \< 0.05, ^∗^p \< 0.01. Scale bars, 100 μm. See also [Figure S2](#app3){ref-type="sec"} and [Tables S1](#app3){ref-type="sec"} and [S2](#app3){ref-type="sec"}.](gr2){#fig2}

![Generation of *SFTPC-GFP* Knockin hPSC Lines\
(A) Strategy for BAC-based gene targeting to produce *SFTPC-GFP* knockin hPSC lines.\
(B) Screening of knockin hPSC lines using TaqMan qPCR. Positive clones with candidate heterozygous deletion of the endogenous *SFTPC* gene are shown in white bars. Only clones that were initially suspected to be positive were tested independently three times.\
(C) Genomic PCR to confirm the removal of the *pgk-NeoR* cassette by Cre-recombinase in the A17-14 and B2-3 *SFTPC-GFP* reporter hPSCs.\
(D) SNP array analysis of the *SFTPC-GFP* knockin hPSC lines. The copy number of *SFTPC* gene loci was analyzed in A17-13, A17-14, and B2-3 clones. The A17-14 and B2-3 clones have two copies of the *SFTPC* gene loci, whereas the A17-13 clone has three copies of the loci. The red dots and y axis represent the normalized signal intensity of each SNP.\
(E) Isolation of SFTPC^−^GFP^+^ and GFP^−^ cells via FACS after sorting CPM^+^ cells via MACS on day 25.\
(F) RT-PCR analyses of GFP^+^ and GFP^−^ sorted cells in the A17-14 and B2-3 *SFTPC-GFP* reporter hPSC lines.\
(G) Representative images of GFP detected in SFTPC^+^, SFTPB^+^, and NKX2-1^+^ cells.\
Error bars show SEM. Scale bars, 100 μm. See also [Figure S3](#app3){ref-type="sec"} and [Tables S1](#app3){ref-type="sec"} and [S2](#app3){ref-type="sec"}.](gr3){#fig3}

![Alveolar Differentiation from CPM^+^ VAFECs in 3D Coculture\
(A) Strategy for inducing AECs via 3D coculture with FHLFs.\
(B) SFTPC-GFP^+^ cells detected in spheroids derived from isolated CPM^+^ VAFECs.\
(C) Transmission electron microscopy of lamellar-body-like structures observed in 3D coculture differentiation of CPM^+^ cells compared with those observed in the adult and fetal murine lungs. Lu, lumen.\
(D) IF staining of spheroids derived from CPM^+^ VAFECs.\
(E) Flow cytometry of SFTPC-GFP^+^ cells in 3D coculture differentiation of CPM^+^ cells or CPM^−^ cells (n = 3).\
(F) GFP^+^ and GFP^−^ cells isolated via FACS, spun down onto slides, and stained by anti-GFP and anti-SFTPC antibodies.\
(G) qRT-PCR comparing the 2D and 3D differentiation into AECs in H9 hESCs and 201B7 (parental), 604A1, and 585A1 hiPSCs. Each value of the gene expression was normalized to the level of *β-ACTIN*. The levels of the fetal lungs were set at one.\
Values are presented as the mean ± SEM. Error bars show SEM. \#p \< 0.05, ^∗^p \< 0.01. Scale bars, 100 μm unless otherwise indicated. See also [Figure S4](#app3){ref-type="sec"} and [Tables S1](#app3){ref-type="sec"} and [S2](#app3){ref-type="sec"}.](gr4){#fig4}
